![Pinterest](https://pinterest.com/pin/create/button/?url=https://bollspel.com/cg-oncology-seeks-investor-support-through-ipo-filing/&media=https://bollspel.com/wp-content/uploads/2024/01/13271-cg-oncology-seeks-investor-support-through-ipo-filing.png&description="CG Oncology is seeking investor support through the filing of an IPO. Learn more about this innovative company and its potential for growth in the oncology field."){kind=link}
Exciting news! Bladder-cancer treatment developer CG Oncology has filed for an initial public offering with the Securities and Exchange Commission.
Based in Irvine, Calif., this biopharmaceutical company is working on a potential therapeutic for bladder-cancer patients who are unresponsive to immunotherapy Bacillus Calmette-Guerin treatment.
Curious about the details? CG Oncology did not disclose how many shares it planned to offer or give an estimated price range, but the company plans to use proceeds primarily for supporting operations.
And that’s not all – the company has applied to list its shares on the Nasdaq Global Market under the ticker CGON. Exciting times ahead!
Keep an eye out for updates -Morgan Stanley, Goldman Sachs & Co., Cantor and Lifesci Capital are acting as the underwriters of the offering.